Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer Transcript

Kyahn Williamson
Senior Vice President of Corporate Communications & Investor Relations

Good morning, good evening or afternoon, depending on where in the world you are. My name is Ky Williamson. I’m SVP of Investor Relations and Corporate Communication at Telix.

Very pleased to welcome you all today to our webinar with some key opinion leaders and special subject matter experts to discuss a physician’s perspective on innovations in PSMA PET CT imaging for prostate cancer.

Today’s format will be a moderated panel discussion hosted by Dr. David Cade, MD, Chief Medical Officer — Group Chief Medical Officer at Telix. I’m very pleased to welcome our speakers. We are joined by Rodney Hicks, Professor of Medicine at the University of Melbourne and Monash University, Founder and Executive Chairman and Chief Medical Officer at the Melbourne Theranostic Innovation Center. and by Dr. Paul Yonover, Chief Data Officer and Director of Clinical Navigation at UroPartners, a division of The Specialty Alliance, Chief of Urology at Ascension Saint Joseph Hospital from Chicago. Thank you for joining us. And last but not least, Darren Patti, the Telix Group Chief Operating Officer.

Today’s format will be a moderated panel discussion, as I said. [Operator Instructions] If we can’t answer your question during the session, we’ll follow up after the call if necessary.

With that, I would like to hand over to David Cade.

David Cade
Group Chief Medical Officer

Thank you, Ky, for the very gracious introduction and very excited to